We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
59.00 | 3.18% | 1,913.00 | 1,916.00 | 1,918.00 | 1,920.00 | 1,861.00 | 1,861.00 | 496,959 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 22.08 | 4.24B |
TIDMHIK
RNS Number : 2004T
Hikma Pharmaceuticals Plc
18 March 2019
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 18 March 2019: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 March 2016 under the 2014 Executive Incentive Plan ("EIP") which was completed on 18 March 2019. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is GBPnil.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Said Darwazah 2 Reason for the notification a) Position/status Executive Chairman b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 45,100 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Mazen Darwazah 2 Reason for the notification a) Position/status Executive Vice Chairman b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 25,406 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Bassam Kanaan 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 26,090 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Khalid Nabilsi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 20,400 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Majda Labadi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 14,530 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Riad Mishlawi 2 Reason for the notification a) Position/status PDMR b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Shares acquired from vesting of the conditional transaction awards on 18 March 2019 under the 2014 EIP. c) Price(s) and Price(s): GBPnil volume(s) Volume(s): 19,890 d) Aggregated information N/A e) Date of the transaction 18 March 2019 f) Place of the London Stock Exchange (XLON) transaction
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBUGDXIGBBGCI
(END) Dow Jones Newswires
March 18, 2019 11:09 ET (15:09 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions